Home > News > Does NanoCrystal Ball See All?
August 10th, 2005
Does NanoCrystal Ball See All?
Abstract:
Jack Uldrich: Shares of Elan (NYSE: ELN) and Motley Fool Stock Advisor recommendation Biogen Idec (Nasdaq: BIIB) jumped 14% and 7%, respectively, on yesterday's news that a recent Elan study found no new confirmed cases of the brain disease, PML, in patients who had taken Tysabri -- a promising multiple sclerosis-fighting drug that was pulled this spring after the deaths of three patients were linked to it.
Tuesday's news obviously bolstered investor confidence that Tysabri will make its way back onto the market, but does that make Elan a good investment opportunity? The answer is "no" in the short term and "yes" in the long term.
Source:
fool.com
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Profiles
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||